EGFR and lung carcinoma: The irreversible covalent binding of neratinib to Cys-797 of EGFR overcomes resistance to the gatekeeper EGFR T790M mutation, a common resistance mechanism to erlotinib or gefitinib in L858R-mutated lung cancer [62,63].